Alpha-Synuclein Ligands for Early Parkinson's Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for neurodegenerative diseases like Parkinson's disease, which are caused by the accumulation of misfolded proteins such as α-synuclein, lack effective early detection and monitoring tools, hindering timely intervention and disease progression evaluation.
Innovation Solution
Development of α-synuclein ligands and their radiolabeled analogs, specifically compounds of Formulas (I)-(VIII), which exhibit high binding affinity to α-synuclein fibrils and are suitable for positron emission tomography (PET) imaging, allowing for the quantification of α-synuclein protein aggregation in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for Parkinson's disease, then clinical symptoms can be detected, but early-stage detection and monitoring capability is insufficient
Solution Approach 1:
The patent applies preliminary action by developing radioligands that can detect α-synuclein aggregation before clinical symptoms manifest. The radioligands bind to misfolded α-synuclein proteins in the brain, enabling detection of the disease in its pre-symptomatic stage through PET imaging, thus allowing early intervention before significant neuronal damage occurs
Solution Approach 2:
The patent replaces mechanical/surgical diagnostic methods with molecular imaging technology. Instead of relying on clinical examinations or post-mortem analysis, the invention uses radiolabeled compounds that emit detectable signals when bound to α-synuclein aggregates, enabling non-invasive, in vivo detection of protein misfolding and aggregation in the living brain
2Measurement precision
If radiolabeled analogs are developed for PET imaging, then quantification of α-synuclein aggregation is enabled, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the radioligand into distinct functional modules: a core structure that binds to α-synuclein fibrils, radiolabel groups for PET detection, and linker regions connecting these components. This modular approach allows systematic optimization of binding affinity and imaging properties while managing molecular complexity through structured design
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the radioligand candidates, including substituent groups, linker lengths, and radiolabel positions. This enables optimization of key parameters such as binding affinity (Kd), selectivity for α-synuclein over other proteins, and imaging signal intensity to achieve accurate quantification of protein aggregation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate early-stage diagnosis and monitoring of synucleinopathies like Parkinson's disease, improving therapeutic intervention enrollment and evaluation of disease progression through precise imaging of α-synuclein protein accumulation.
Implementation Method 1
compounds that function as ligands for α-synuclein... exhibit high binding affinity to α-synuclein fibrils
Data Source
AI summary
The present invention generally relates to various compounds that are useful as α-synuclein ligands. The invention further relates to methods of using these compounds and their radiolabeled analogs for the detection of synucleinopathies, including Parkinson's disease (PD).